Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1568-1577

  Burt, Bryan M ^a   Bader, Andrew ^a   Winter, Daniel ^a   Rodig, Scott J ^a   Bueno, Raphael ^a   Sugarbaker, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; STAT6 PROTEIN; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG RESECTION; PLEURA MESOTHELIOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

CELL LINE, TUMOR; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MESOTHELIOMA; PLEURAL NEOPLASMS; PROGNOSIS;

EID: 84858272601     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1808     Document Type: Article

References (48)

1. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
2. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-31. (Pubitemid 28130949)
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
4. Carbone M, Kratzke RA, Testa JR, Elmishad AG, Chen Y, Liu Z, et al. The pathogenesis of mesothelioma. Semin Oncol 2002;29:2-17. (Pubitemid 34163530)
5. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A 2006;103:10397-402. (Pubitemid 44051178)
6. Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L, Keshavjee S, et al. Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2008;135: 823-9. (Pubitemid 351417931)
7. Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011;117:5234-44.
8. Kawakami K, Kawakami M, Puri RK. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 2001;21:299-310. (Pubitemid 32959368)
9. Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, et al. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res 2002;8:3503-11. (Pubitemid 35340728)
10. Kioi M, Takahashi S, Kawakami M, Kawakami K, Kreitman RJ, Puri RK. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy. Cancer Res 2005;65:8388-96. (Pubitemid 41330605)
11. Strome SE, Kawakami K, Alejandro D, Voss S, Kasperbauer JL, Salomao D, et al. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models. Clin Cancer Res 2002;8:281-6. (Pubitemid 34101489)
12. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins. J Immunol 2004;172:5467-77. (Pubitemid 38542047)
13. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999;21:339-59. (Pubitemid 30011443)
14. Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, et al. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg 2004;78:436-43. (Pubitemid 38980748)
15. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005;166:1827-40. (Pubitemid 40734405)
16. Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 1989;74: 940-6. (Pubitemid 19210007)
17. De Rienzo A, Dong L, Yeap BY, Jensen RV, Richards WG, Gordon GJ, et al. Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2011;17:310-6.
18. Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol 2009;6:415-22.
19. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Ann Rev Immunol 1999;17:701-38. (Pubitemid 29241138)
20. Kawakami K, Leland P, Puri RK. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 2000;60:2981-7. (Pubitemid 30395824)
21. Prokopchuk O, Liu Y, Henne-Bruns D, Kornmann M. Interleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions. Br J Cancer 2005;92:921-8. (Pubitemid 40462640)
22. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006;116: 2777-90. (Pubitemid 44511641)
23. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009;182:6562-8.
24. Li Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 2008;68:8687-94.
25. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93. (Pubitemid 26372655)
26. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-44. (Pubitemid 37323214)
27. Kienzle N, Olver S, Buttigieg K, Grobes P, Janas ML, Baz A, et al. Progressive differentiation and commitment of CD8+ T cells to a poorly cytolytic CD8low phenotype in the presence of IL-4. J Immunol 2005;174:2021-9. (Pubitemid 40223944)
28. Asselin-Paturel C, Echchakir H, Carayol G, Gay F, Opolon P, Grunenwald D, et al. Quantitative analysis of Th1, Th2 and TGF-beta1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998;77:7-12. (Pubitemid 28308544)
29. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63:366-71.
30. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoural immune response in fresh tumourinfiltrating lymphocytes from human gliomas. Clin Exp Immunol 1996;105:344-52. (Pubitemid 26246956)
31. Koller FL, Hwang DG, Dozier EA, Fingleton B. Epithelial interleukin-4 receptor expression promotes colon tumor growth. Carcinogenesis 2010;31:1010-7.
32. Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998;160:5869-73. (Pubitemid 28298045)
33. Schuler T, Qin Z, Ibe S, Noben-Trauth N, Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med 1999;189: 803-10. (Pubitemid 29189685)
34. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 1993;91:88-93. (Pubitemid 23037257)
35. Toi M, Bicknell R, Harris AL. Inhibition of colon and breast carcinoma cell growth by interleukin-4. Cancer Res 1992;52:275-9.
36. Tepper RI, Levinson DA, Stanger BZ, Campos-Torres J, Abbas AK, Leder P. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 1990;62:457-67.
37. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254: 713-6. (Pubitemid 21917394)
38. Monti G, Jaurand MC, Monnet I, Chretien P, Saint-Etienne L, Zeng L, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 1994;54: 4419-23. (Pubitemid 24273156)
39. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 1999;59:367-71. (Pubitemid 29048869)
40. DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005;4: 342-6. (Pubitemid 41351297)
41. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992;51: 296-301.
42. Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-75. (Pubitemid 32266815)
43. Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel DT, Nishimoto N. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer 2006;119:1303-11. (Pubitemid 44258804)
44. Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77: 907-12. (Pubitemid 28101778)
45. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 2010;5: 479-83.
46. Husain SR, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med 1999;5:817-22.
47. Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA. Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity. Br J Cancer 2009;101:1114-23.
48. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin- 4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000;6:2157-65. (Pubitemid 30399180)